Business
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
- Practice integrated neurology network expands enrollment capacity - POTOMAC, MARYLAND / ACCESS Newswire / February 23, 2026 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced the addition of Visionary Investigators Network ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"- Practice integrated neurology network expands enrollment capacity -","length":69,"tagName":"p"},{"type":"text","content":"POTOMAC, MARYLAND / ACCESS Newswire / February 23, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced the addition of Visionary Investigators Network ("VIN") as a clinical research site participating in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease dementia.","length":405,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1504,"height":890,"url":"https://media.zenfs.com/en/accesswire.ca/2d6f79cdc0f62692856e4ba36b7a5dce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/r_zXitsvgGLYuXB1dGMucQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/2d6f79cdc0f62692856e4ba36b7a5dce","width":960,"height":568},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/94ZclpALpzNqSHQ4zNv2dQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDIwO2NmPXdlYnA-/https://media.zenfs.com/en/accesswire.ca/2d6f79cdc0f62692856e4ba36b7a5dce","width":1200,"height":710}},"href":"https://app.accessnewswire.com/imagelibrary/63b27f32-cb2e-464b-bf0e-6df10e638215/igc-pharma-inc-2025.png","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"VIN operates clinical research programs embedded within established private neurology practices, providing access to well-characterized patient populations while maintaining continuity of clinical care. IGC Pharma believes this practice-integrated model supports efficient enrollment, sustained patient engagement, and consistent protocol adherence as the CALMA trial advances. The Company recently reported approximately 70% of planned enrollment is completed.","length":461,"tagName":"p"},{"type":"text","content":""The CALMA trial continues as designed, and our focus is execution through enrollment completion," said Ram Mukunda, CEO of IGC Pharma. "VIN brings an experienced, practice-integrated research model that aligns well with our Phase 2 execution priorities and supports continued enrollment momentum.","length":312,"tagName":"p"},{"type":"text","content":"VIN - Coconut Gr...